<DOC>
	<DOCNO>NCT00049790</DOCNO>
	<brief_summary>The purpose study determine safety efficacy rhAngiostatin protein administer combination paclitaxel carboplatin patient non-small-cell lung cancer .</brief_summary>
	<brief_title>Safety Efficacy Study rhAngiostatin Administered Combination With Paclitaxel Carboplatin Patients With Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Angiostatins</mesh_term>
	<criteria>Inclusion : Histological cytological confirm Stage IIIB NSCLC malignant pleural effusion , Stage IV NSCLC recurrent NSCLC No previous chemotherapy NSCLC Have one lesion bidimensionally measurable physical exam , MRI , CT great 1 cm diameter Specified lab parameter Life expectancy least 12 week ECOG performance status 0 1 Understand requirement study Agree use effective contraceptive method Exclusion : Have CNS metastasis Have active cancer addition ot NSCLC Participated clinical trial involve conventional investigational drug within previous 4 week Have contraindication paclitaxel carboplatin Have Grade 3 great peripheral neuropathy Be pregnant lactate Have history myocardial infarction angina pectoris/angina last 6 month Have significant ( 30 mL ) hemoptysis past 3 month Have active infection Have history bleed diathesis , hypercoagulable condition , active bleeding disorder Be receive concurrent treatment therapeutic dos heparin coumadin Have major surgery within 4 week state therapy Have additional uncontrolled serious medical condition psychiatric illness Received rhAngiostatin clinical protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Advanced non-small cell lung cancer</keyword>
</DOC>